Keyword: Salix Pharmaceuticals
Salix Pharmaceuticals President Mark McKenna is leaving Bausch Health for a precision medicine company.
Dova slashes the price of its platelet-boosting drug Doptelet as it gears up to challenge Novartis' Promacta.
The inflatable stolen colon is back in triplicate thanks to Salix Pharmaceutical employees.
Salix's latest deal not only beefs up its own portfolio, but gives Dova a co-promo boost for its newly minted chronic liver disease drug, Doptelet.
Salix and US WorldMeds’ launch for first-ever opioid withdrawal drug Lucemyra is tightly focused for now, but they're eyeing the mainstream next.
US WorldMeds needed a partner to help launch its first-ever opioid withdrawal med Lucemyra, and Valeant’s Salix has taken the job.
Salix Pharmaceuticals' research found that many people who might have IBS are undiagnosed, leading to a show about IBS-D on the Lifetime Channel.
Ready for a 3D tour of the human gastrointestinal tract? Valeant's Salix Pharmaceuticals has a new virtual reality tool that can take you there.
Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, triggering a 20% run-up in its share price.
Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may not be so easy.